Suppression of Tumorigenicity 14 (Colon Carcinoma) Proteine (ST14)

The protein encoded by ST14 is an epithelial-derived, integral membrane serine protease. Zusätzlich bieten wir Ihnen Suppression of Tumorigenicity 14 (Colon Carcinoma) Antikörper (106) und Suppression of Tumorigenicity 14 (Colon Carcinoma) Kits (9) und viele weitere Produktgruppen zu diesem Protein an.

alle Proteine anzeigen Gen GeneID UniProt
ST14 6768 Q9Y5Y6
ST14 19143 P56677
Ratte ST14 ST14 114093  
Direkt bei antikoerper-online bestellen
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Online bestellen

Top Suppression of Tumorigenicity 14 (Colon Carcinoma) Proteine auf

Showing 4 out of 7 products:

Katalog Nr. Origin Quelle Konjugat Bilder Menge Anbieter Lieferzeit Preis Details
Insektenzellen Maus rho-1D4 tag „Crystallography Grade“ protein due to multi-step, protein-specific purification process 0.25 mg Anmelden zum Anzeigen 60 bis 65 Tage
Insektenzellen Human rho-1D4 tag „Crystallography Grade“ protein due to multi-step, protein-specific purification process 0.5 mg Anmelden zum Anzeigen 60 bis 65 Tage
Escherichia coli (E. coli) Human His tag 100 μg Anmelden zum Anzeigen 15 bis 18 Tage
Wheat germ Human GST tag 10 μg Anmelden zum Anzeigen 11 bis 12 Tage

ST14 Proteine nach Spezies und Herkunft

Origin Exprimiert in Konjugat
Human , ,
, ,
Mouse (Murine)

Weitere Proteine zu Suppression of Tumorigenicity 14 (Colon Carcinoma) (ST14) Interaktionspartnern

Human Suppression of Tumorigenicity 14 (Colon Carcinoma) (ST14) Interaktionspartner

  1. the data strongly advocate this ST14 variant as the underlying genetic cause of autosomal recessive ichthyosis with hypotrichosis syndrome in this first reported affected family from Pakistan. Moreover, the present study adds to the spectrum of mutations in the ST14 gene, implicating them in the pathogenesis of autosomal recessive ichthyosis with hypotrichosis syndrome.

  2. limited role for HAI-2 in the inhibition of matriptase and prostasin is the result of its primarily intracellular localization in basal and spinous layer keratinocytes, which probably prevents the Kunitz inhibitor from interacting with active prostasin or matriptase

  3. Abrogation of matriptase expression by silencing with RNAi or inhibition of matriptase proteolytic activity with a synthetic inhibitor impairs the conversion of inactive pro-HGF to active HGF and subsequent c-Met-mediated signaling.

  4. Data, including data from studies using cadaver tissue, suggest that matriptase and matriptase mRNA are expressed in several regions of the brain with an enrichment in neurons; higher levels of matriptase RNA are expressed in young individuals as compared to older individuals; matriptase cleaves amyloid beta precursor protein at a specific arginine residue (Arg-102).

  5. Activation of proHGF by St14 induces mouse embryonic stem cell differentiation.

  6. The authors report that ST14/Prss14 is an emerging therapeutic target for breast cancer where HER2 is not applicable.

  7. These results identify EpCAM as a substrate of matriptase and link HAI-2, matriptase, EpCAM, and claudin-7 in a functionally important pathway that causes disease when it is dysregulated.

  8. Matriptase is present in macrophages from patients with mutated alpha-1 antitrypsin at high levels and contributes to their proteolytic activity on extracellular matrix. MMP-14 is a novel substrate for matriptase, which regulates the levels of MMP-14 on the cell surface. High levels of matriptase may contribute to increased ECM degradation by Z-M, both directly and through MMP-14 activation.

  9. Ultraviolet irradiation/reactive oxygen species induced matriptase proteolysis may have short term protective effects and contribute to the recovery from acute epidermal damage and/or pathology of skin with chronic sun damage.

  10. The present study demonstrated that ovarian cancer cell metastasis and invasion were more dependent on upregulation of matriptase levels than downregulation of HAI1. Matriptase may be a potential adjuvant therapeutic target for inhibiting ovarian cancer invasion and metastasis.

  11. Given that matriptase-1 participates in terminal KC differentiation, its absence in psoriatic skin lesions indicates that this contributes to the barrier disturbances in this disease.

  12. Novel findings reveal a new paradigm in matriptase activation involving PDGF-D-specific signal transduction leading to extracellular acidosis.

  13. Maritriptase is required for pro-HGF/c-Met signaling and cell proliferation in breast cancer cells.

  14. Matriptase inhibition by HAI-2 requires the translocation of HAI-2 to the cell surface, a process which is observed in some breast cancer cells but not in mammary epithelial cells.

  15. prostate cancer cell invasion is stimulated by a rapid but sustained increase in Src activity, mediated non-genomically by cytoplasmic AR, leading to rapid activation and shedding of the laminin protease Matriptase

  16. Report potent/specific inhibition of matriptase by the cyclic microprotein MCoTI-II.

  17. Matriptase expression correlates with tumour progression and invasive capability in oral squamous cell carcinoma

  18. Matriptase can act as a cellular sensor of the chemical environment of the cell that allows the cell to respond to and protect itself from changes in the chemical milieu.

  19. It presents evidence that matriptase efficiently cleaves the HR1 portion of gp41 into a 22-residue chemotactic peptide MAT-1, the sequence of which is highly conserved across HIV-1 clades.

  20. Dysregulated pericellular proteolysis as a result of unregulated matriptase expression with limited HAI-1 may contribute to the pathological characteristics of several human B-cell lymphomas.

Suppression of Tumorigenicity 14 (Colon Carcinoma) (ST14) Protein Überblick

Protein Überblick

The protein encoded by this gene is an epithelial-derived, integral membrane serine protease. This protease forms a complex with the Kunitz-type serine protease inhibitor, HAI-1, and is found to be activated by sphingosine 1-phosphate. This protease has been shown to cleave and activate hepatocyte growth factor/scattering factor, and urokinase plasminogen activator, which suggest the function of this protease as an epithelial membrane activator for other proteases and latent growth factors. The expression of this protease has been associated with breast, colon, prostate, and ovarian tumors, which implicates its role in cancer invasion, and metastasis.

Genbezeichner und Symbole assoziert mit ST14

  • suppression of tumorigenicity 14 (ST14)
  • suppression of tumorigenicity 14 L homeolog (st14.L)
  • suppression of tumorigenicity 14 (colon carcinoma) (St14)
  • suppression of tumorigenicity 14 (St14)
  • Epithin Protein
  • hai Protein
  • matriptase Protein
  • mCAP3 Protein
  • mt-sp1 Protein
  • mtsp1 Protein
  • Prss14 Protein
  • snc19 Protein
  • st14 Protein
  • st14a Protein
  • tadg15 Protein
  • tmprss1 Protein
  • Tmprss14 Protein
  • XMT-SP1 Protein

Bezeichner auf Proteinebene für ST14

membrane-type serine protease 1 , prostamin , serine protease 14 , serine protease TADG-15 , suppression of tumorigenicity 14 (colon carcinoma, matriptase, epithin) , suppressor of tumorigenicity 14 protein , tumor associated differentially expressed gene 15 protein , tumor-associated differentially-expressed gene 15 protein , matriptase a , suppression of tumorigenicity 14 (colon carcinoma) a , suppressor of tumorigenicity 14 protein homolog , suppressor of tumorigenicity protein 14 , matriptase/MT-SP1 , protease, serine, 14 (epithin) , matriptase , membrane-type serine protease

100101609 Oryctolagus cuniculus
6768 Homo sapiens
394363 Xenopus laevis
767617 Bos taurus
19143 Mus musculus
114093 Rattus norvegicus
Ausgewählte Anbieter für Suppression of Tumorigenicity 14 (Colon Carcinoma) Proteine (ST14)
Haben Sie etwas anderes gesucht?